The 20 fastest-growing, highest-paying biotechs
Hello,
Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, and today in healthcare news:
- We rounded up the 20 fastest growing drugmakers that pay the most;
- The recently approved Alzheimer's treatment could change the way we pay for drugs;
- 5 questions facing GlaxoSmithKline ahead of a big investor meeting.
If you're new to this newsletter, sign up here. Comments, tips? Email me at lramsey@insider.com or tweet @lydiaramsey125. Let's get to it…
FILE PHOTO: A technician works with genome samples at a lab of the biotech company Sinogene in Beijing
Reuters
Here are the 20 fastest growing biotech and pharma companies that pay people the most
Reuters
- Insider analyzed data from more than 100 drug companies to find which were hiring and paying top wages.
- We found 20 companies that are hiring and typically pay more than $217,000.
- The list includes cancer companies, gene-editing firms, neuroscience startups, and vaccine developers.
Dr. William Burke goes over a PET brain scan at Banner Alzheimers Institute in Phoenix. Biogen's drug was tested against carriers of the APOE gene, which is linked to Alzheimer's, and non-carriers.
Matt York/Associated Press
Matt York/Associated Press
Big insurers are considering new ways to pay for Biogen's $56,000-per-year Alzheimer's drug. It could spark changes in how the US and insurers pay for drugs.
- The price tag of new Alzheimer's drug Aduhelm could squeeze Medicare and patients.
- Experts say the cost could prompt Medicare and private insurers to find new ways to pay for drugs.
- Insurers Cigna and Humana are considering contracts to pay for the drug based on how well it works.
GlaxoSmithKline CEO Emma Walmsley.
Mandel Ngan/Getty Images
Mandel Ngan/Getty Images
5 burning questions facing pharma giant GlaxoSmithKline and CEO Emma Walmsley before a crucial investor day
- Leaders of GlaxoSmithKline will present their vision for the pharma giant on Wednesday.
- GSK has faced mounting questions over its vaccine business and cancer-research strategy.
We're watching for five pressing questions that GSK may attempt to answer>>
More stories we're reading:
- The Delta variant might pose the biggest threat yet to vaccinated people (Insider)
- Why an FDA advisory committee member isn't resigning following a controversial Alzheimer's approval (Stat News)
- Supreme Court upholds the Affordable Care Act, ruling that Texas doesn't have standing to challenge Obama's signature healthcare law (Insider)
- Struggling hospitals could be a key part of why a disproportionate number of people who've died from COVID-19 are Black (BuzzFeed News)
- 23andMe just went public. We spoke with its CEO about its road to IPO, and what the future holds for the consumer-genetics industry. (Insider)
– Lydia
Read the original article on Business Insider